Stocktoria
Entrada Therapeutics, Inc. TRDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-29
Entrada Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| R&D expense | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Income tax | $924,000 | $859,000 | $18.7M | $0 | $0 |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| EPS (diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
Source: SEC EDGAR filings · CIK 0001689375 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.